Key TakeawaysShares of Viking Therapeutics surged Wednesday after J.P. Morgan analysts initiated coverage of the drugmaker at "overweight" and shared an optimistic view.Viking is developing weight-loss drugs that have boosted its stock after positive trial results since the start of this year, and analysts say it might happen again.In the long term, analysts predict that Viking's anticipated oral weight-loss drug could claim about 10% of the market in the years following its projected 2030 release. Viking T ...